About EYLEA Results of phase 3 clinical trials are presented for EYLEA.1 See the data

Available for Order in
a Pre-filled Syringe

EYLEA® (aflibercept) pre-filled syringe and packaging.

Trust ≈8 Years of Extensive Clinical Experience and the Integrity of Data From Large, Well-Controlled Trials1

The Established Experience of EYLEA1,9
  • ≈8 years of real-world experience1
  • An estimated ≈9 million doses administered to ≈790,000 eyes since launch (and counting)9
  • 8 phase 3 clinical trials including more than 3000 EYLEA-treated patients across all approved indications1
Accessing EYLEA Comprehensive support for you and your patients. Find support
Patient support for EYLEA. Patient Support

We're committed to help ensure your eligible patients have access to EYLEA. 

Support for the reimbursement process. Reimbursement

Get information about navigating the reimbursement process. Find enrollment forms, learn about PA assistance, and more. 

Product support for Eylea. Product Support

Find complete product support—guiding you through orders, returns, and more. 

News Stay informed on current EYLEA clinical information, events, and more. Read the latest
06 DEC 19
Available for Order in a Pre-Filled Syringe
  • anti-VEGF = anti–vascular endothelial growth factor
  • AMD = Age-related Macular Degeneration
  • MEfRVO = Macular Edema following Retinal Vein Occlusion (includes Branch Retinal Vein Occlusion [BRVO] and Central Retinal Vein Occlusion [CRVO])
  • DME = Diabetic Macular Edema
  • DR = Diabetic Retinopathy
See More Important Safety Information and Indications
  • CONTRAINDICATIONS: EYLEA® (aflibercept) Injection is contraindicated in patients with ocular or periocular infections, active intraocular inflammation, or known hypersensitivity to aflibercept or to any of the excipients in EYLEA.
Important Safety Information INDICATIONS

EYLEA® (aflibercept) Injection 2 mg (0.05 mL) is indicated for the treatment of patients with Neovascular (Wet) Age-related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), and Diabetic Retinopathy (DR).

Please see the full Prescribing Information for EYLEA.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

The information provided in this site is intended only for healthcare professionals in the United States. The products discussed herein may have different product labeling in different countries.

References
  1. EYLEA® (aflibercept) Injection full U.S. Prescribing Information. Regeneron Pharmaceuticals, Inc. August 2019.
  2. Heier JS, Brown DM, Chong V, et al; for the VIEW 1 and VIEW 2 Study Groups. Intravitreal aflibercept (VEGF Trap-Eye) in wet age-related macular degeneration. Ophthalmology. 2012;119(12):2537-2548.
  3. Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology. 2014;121(1):193-201.
  4. Khurana RN, Rahimy E, Joseph WA, et al. Extended (every 12 weeks or longer) dosing interval with intravitreal aflibercept and ranibizumab in neovascular age-related macular degeneration: post hoc analysis of VIEW trials. Am J Ophthalmol. 2019;200:161-168.
  5. Brown DM, Schmidt-Erfurth U, Do DV, et al. Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies. Ophthalmology. 2015;122(10):2044-2052.
  6. Campochiaro PA, Clark WL, Boyer DS, et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study. Ophthalmology. 2015;122(3):538-544.
  7. Boyer D, Heier J, Brown DM, et al. Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study. Ophthalmology. 2012;119(5):1024-1032.
  8. Holz FG, Roider J, Ogura Y, et al. VEGF Trap-Eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study. Br J Ophthalmol. 2013;97(3):278-284.
  9. Data on file. Regeneron Pharmaceuticals, Inc.
  10. Jaffe GJ, Kaiser PK, Thompson D, et al. Differential response to anti-VEGF regimens in age-related macular degeneration patients with early persistent retinal fluid. Ophthalmology. 2016;123(9):1856-1864.